<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1483</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>9029109</PubmedId>
            <Abstract>Influenza A/Puerto Rico/8/34 nucleoprotein (NP) contains an H-2Kd-restricted CD8+ T cell (T CD8+) epitope spanning amino acid residues 147-155. It was previously demonstrated that expression of NP147-155 and NP147-158 in isolation via "minigene"/recombinant vaccinia virus (vac) technology leads to sensitization of target cells for NP-specific killing while expression of 147-158 lacking the arginine at position 156 (termed here as 147-155TG) does not. The presentation block was overcome by placing this fragment into the context of full length NP. We show that addition of a single amino acid, Met159, to the C terminus of the blocked peptide (creating 147-155TGM) restores presentation. Presentation of 147-155TGM was not due to trimming in the exocytic compartment, consistent with severe limitations on C-terminal trimming activity in this location. Rescued presentation was also achieved when the blocked construct was extended in the N-terminal direction only, but in this case more than 55 amino acids of flanking sequence were required. The transition to presentation was abrupt, with 91-155TG and shorter constructs showing little or no detectable presentation and 90-155TG showing full level presentation. Presentation could not be attributed to acquisition of conventional targets for ubiquitination since mutation of all Lys residues, to which the ubiquitin moiety is conjugated, does not abrogate presentation. Rescued presentation was not inhibited by the peptide aldehyde N-acetyl-L-leucinyl-L-leucinal-L-norleucinal, suggesting that the added elements may be recruiting nonproteasomal activity. We have therefore identified and begun to characterize protease targeting of regulatory elements, both local and distal to an epitope, which strongly influence the ability of the epitope to be excised.</Abstract>
            <ArticleYear>1997</ArticleYear>
            <ArticlePages>1727-33</ArticlePages>
            <ArticleTitle>Regulation of class I-restricted epitope processing by local or distal flanking sequence.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Yellen-Shaw</LastName>
                    <ForeName>A J</ForeName>
                </Author>
                <Author>
                    <LastName>Eisenlohr</LastName>
                    <ForeName>L C</ForeName>
                </Author>
            </Authors>
            <Affiliations>Kimmel Cancer Institute, Jefferson Medical College, Philadelphia, PA 19107, USA.</Affiliations>
            <ArticleChemicalList>Epitopes;H-2 Antigens;NP protein, Influenza A virus;Nucleoproteins;RNA-Binding Proteins;Viral Core Proteins;Endopeptidases</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence(physiology); Animals; Antigen Presentation(drug effects; genetics); Endopeptidases(immunology; physiology); Epitopes(drug effects; genetics; metabolism); Exocytosis(immunology); H-2 Antigens(drug effects; genetics; metabolism); Humans; Influenza A virus(immunology); Mice; Mice, Inbred BALB C; Molecular Sequence Data; Nucleoproteins(genetics; immunology; metabolism); RNA-Binding Proteins; Substrate Specificity(immunology); T-Lymphocytes, Cytotoxic(enzymology; metabolism; virology); Viral Core Proteins(genetics; immunology; metabolism)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>158</Volume>
                <Issue>4</Issue>
                <Title>Journal of immunology (Baltimore, Md. : 1950)</Title>
                <Issn>0022-1767</Issn>
                <MedlineTa>J Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>M147-155</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>MTYQRTALV</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <EpitopeRelatedObject>
                    <RelatedObjectType>The epitope is an analog of:</RelatedObjectType>
                    <RelatedObject>
                        <FragmentOfANaturalSequenceMolecule>
                            <ChemicalType>Peptide from protein</ChemicalType>
                            <LinearSequence>TYQRTRALV</LinearSequence>
                            <StartingPosition>147</StartingPosition>
                            <EndingPosition>155</EndingPosition>
                            <SourceMolecule>
                                <IedbAccession>SRC124</IedbAccession>
                            </SourceMolecule>
                            <SourceOrganismId>211044</SourceOrganismId>
                        </FragmentOfANaturalSequenceMolecule>
                    </RelatedObject>
                </EpitopeRelatedObject>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>42902</EpitopeId>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>This peptide is composed of Influenza A/Puerto Rico/8/34 NP 147-155 preceded by a methionine.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>1022889</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <IedbAccession>SRC124</IedbAccession>
                                            </Molecule>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Nucleoprotein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Internal Identifier-no external match available</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>10245</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>Details regarding the production of the CTL populations were described in a previous reference.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>P815-Mast cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>M147-155</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <SequenceMoleculeNoNaturalSource>
                                        <ChemicalType>Peptide, no natural source</ChemicalType>
                                        <LinearSequence>MTYQRTALV</LinearSequence>
                                    </SequenceMoleculeNoNaturalSource>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <RecombinantOrganism>
                                    <SubType>Recombinant Organism</SubType>
                                    <RecombinantOrganismId>10245</RecombinantOrganismId>
                                </RecombinantOrganism>
                            </AntigenContainingObject>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Presentation was shown not to occur in the exocytic compartment.  Presentation could not be attributed to acquisition of conventional targets for ubiquitination since mutation of all Lys residues, to which the ubiquitinmoiety is conjugated, did not abrogate presentation. Rescued presentation was not inhibited by the peptide aldehyde N-acetyl-L-leucinyl-L-leucinal-L-norleucinal, suggesting that the added elements may be recruiting nonproteasomal activity.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>M147-155TG</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>MTYQRTALVTG</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <EpitopeRelatedObject>
                    <RelatedObjectType>The epitope is an analog of:</RelatedObjectType>
                    <RelatedObject>
                        <FragmentOfANaturalSequenceMolecule>
                            <ChemicalType>Peptide from protein</ChemicalType>
                            <LinearSequence>TYQRTRALVRTG</LinearSequence>
                            <StartingPosition>147</StartingPosition>
                            <EndingPosition>158</EndingPosition>
                            <SourceMolecule>
                                <IedbAccession>SRC124</IedbAccession>
                            </SourceMolecule>
                            <SourceOrganismId>11320</SourceOrganismId>
                        </FragmentOfANaturalSequenceMolecule>
                    </RelatedObject>
                </EpitopeRelatedObject>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>42903</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>This peptide is composed of Influenza A/Puerto Rico/8/34 NP 147-155 preceded by a methionine, and and followed by a threonine and glycine (residues 157 and 158 of the NP protein).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>1022890</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <IedbAccession>SRC124</IedbAccession>
                                            </Molecule>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Nucleoprotein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Internal Identifier-no external match available</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>10245</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>Details regarding the production of the CTL populations were described in a previous reference.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>P815-Mast cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>169</MhcAlleleId>
                            <MhcEvidenceCode>T cell assay -Biological process measured</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>M147-155TG</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <SequenceMoleculeNoNaturalSource>
                                        <ChemicalType>Peptide, no natural source</ChemicalType>
                                        <LinearSequence>MTYQRTALVTG</LinearSequence>
                                    </SequenceMoleculeNoNaturalSource>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <RecombinantOrganism>
                                    <SubType>Recombinant Organism</SubType>
                                    <RecombinantOrganismId>10245</RecombinantOrganismId>
                                </RecombinantOrganism>
                            </AntigenContainingObject>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Placing this peptide into the context of the full-length NP molecule was shown to restore the presentation of the epitope.  An array of minigenes encoding polypeptides in which the unprocessed epitope was extended by varying lengths toward either the C terminus the N terminus of the NP molecule were also tested.  Methionine corresponding to NP residue 159, was sufficient to restorepresentation of the epitope.  All longer constructs tested, which included extensions stretching to residues 163, 168, 176, 186, 213, 315, and 498 were also presented. .</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>M147-155TGM</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>MTYQRTALVTGM</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <EpitopeRelatedObject>
                    <RelatedObjectType>The epitope is an analog of:</RelatedObjectType>
                    <RelatedObject>
                        <FragmentOfANaturalSequenceMolecule>
                            <ChemicalType>Peptide from protein</ChemicalType>
                            <LinearSequence>TYQRTRALVRTGM</LinearSequence>
                            <StartingPosition>147</StartingPosition>
                            <EndingPosition>159</EndingPosition>
                            <SourceMolecule>
                                <IedbAccession>SRC124</IedbAccession>
                            </SourceMolecule>
                            <SourceOrganismId>211044</SourceOrganismId>
                        </FragmentOfANaturalSequenceMolecule>
                    </RelatedObject>
                </EpitopeRelatedObject>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>42904</EpitopeId>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>This peptide is composed of Influenza A/Puerto Rico/8/34 NP 147-155 preceded by a methionine, and and followed by a threonine, glycine,and methionine (residues 157, 158, and 159 of the NP protein).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>1022891</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Structurally Related</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <IedbAccession>SRC124</IedbAccession>
                                            </Molecule>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Nucleoprotein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Internal Identifier-no external match available</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>10245</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                            </InVitroAdministration>
                            <ImmunizationComments>Details regarding the production of the CTL populations were described in a previous reference.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>P815-Mast cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>M147-155TGM</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <SequenceMoleculeNoNaturalSource>
                                        <ChemicalType>Peptide, no natural source</ChemicalType>
                                        <LinearSequence>MTYQRTALVTGM</LinearSequence>
                                    </SequenceMoleculeNoNaturalSource>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <RecombinantOrganism>
                                    <SubType>Recombinant Organism</SubType>
                                    <RecombinantOrganismId>10245</RecombinantOrganismId>
                                </RecombinantOrganism>
                            </AntigenContainingObject>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>An array of minigenes encoding polypeptides in which the unprocessed epitope was extended by varying lengths toward either the C terminus the N terminus of the NP molecule tested.  Although using the epitope followed by threonine and glycine representing residues 157 and 158 of NP blocked preocessing and presentation, methionine corresponding to NP residue 159, was sufficient to restore presentation of the epitope.  Presentation was shown not to occur in the exocytic compartment.  Presentation could not be attributed to acquisition of conventional targets for ubiquitination since mutation of all Lys residues, to which the ubiquitin moiety is conjugated, did not abrogate presentation. Rescued presentation was not inhibited by the peptide aldehyde N-acetyl-L-leucinyl-L-leucinal-L-norleucinal, suggesting that the added elements may be recruiting nonproteasomal activity.  All longer constructs tested, which included extensions stretching to residues 163, 168, 176, 186, 213, 315, and 498 were also presented.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

